Follow us on Twitter
twitter icon@FreshPatents


Psychiatric patents

      

This page is updated frequently with new Psychiatric-related patent applications.

SALE: 95+ Psychiatric-related patent PDFs



 Substituted prolines / piperidines as orexin receptor antagonists patent thumbnailSubstituted prolines / piperidines as orexin receptor antagonists
The present invention is directed to compounds that modulate the bioactivity of an orexin receptor such as ox1 or ox2, or both; to pharmaceutical compositions and combinations comprising a compound of the invention; to methods of treatment of malconditions in patients wherein modulation of an orexin receptor is medically indicated; and to methods of preparation of compounds of the invention. For example, orexin receptor-modulatory compounds of the present invention can be used in treatment of an eating disorder, obesity, alcoholism or an alcohol-related disorder, drug abuse or addiction including addiction to cocaine, opiates, amphetamines, or nicotine, a sleep disorder, a cognitive dysfunction in a psychiatric or neurologic disorder, depression, anxiety, panic disorder, schizophrenia, alzheimer's disease, parkinson's disease, huntington's chorea, headache, migraine, pain, gastrointestinal diseases, epilepsy, inflammations, immune-related diseases, endocrine-related diseases, cancer, hypertension, behavior disorder, mood disorder, manic depression, dementia, sex disorder, psychosexual disorder, or renal disease..
Eolas Therapeutics, Inc.


 Tetrahydroprotoberbine compounds and uses thereof in the treatment of neurological, psychiatric and neurodegenerative diseases patent thumbnailTetrahydroprotoberbine compounds and uses thereof in the treatment of neurological, psychiatric and neurodegenerative diseases
Tetrahydroprotoberbine (thpb) compounds and their use in the treatment of neurological, psychiatric and neurodegenerative diseases is provided. The compounds include d-govadine, l-govadine and racemic govadine, as well as d-thpbs of general formula (i).

 Novel tricyclic modulators of cannabinoid receptors patent thumbnailNovel tricyclic modulators of cannabinoid receptors
The compounds of the invention are modulators of cannabinoid receptors cb1 or cb2. The compounds can be used for the prevention or treatment of, e.g., pain, cancer, skin diseases, weight-associated disorders, chemical addictions, psychiatric disorders, neurodegenerative disorders, bone diseases, and inflammatory diseases.
The University Of Montana


 Engineered light-activated anion channel proteins and methods of use thereof patent thumbnailEngineered light-activated anion channel proteins and methods of use thereof
Aspects of the disclosure include compositions, devices, systems and methods for optogenetic modulation of action potentials in target cells. The subject devices include light-generating devices, control devices, and delivery devices for delivering light-responsive polypeptides, or nucleic acids encoding same, to target cells.
The Board Of Trustees Of The Leland Stanford Junior University


 Peptides as oxytocin agonists patent thumbnailPeptides as oxytocin agonists
The present compounds compounds are oxytocin receptor agonists for the treatment of autism, stress, including post traumatic stress disorder, anxiety, including anxiety disorders and depression, schizophrenia, psychiatric disorders and memory loss, alcohol withdrawal, drug addiction and for the treatment of prader-willi syndrome.. .
Hoffmann-la Roche Inc.


 Peptides as oxytocin agonists patent thumbnailPeptides as oxytocin agonists
The present compounds are oxytocin receptor agonists for the treatment of autism, stress, including post-traumatic stress disorder, anxiety, including anxiety disorders and depression, schizophrenia, psychiatric disorders and memory loss, alcohol withdrawal, drug addiction and for the treatment of prader-willi syndrome.. .
Hoffmann-la Roche Inc.


 Pde9 inhibitors with imidazo triazinone backbone patent thumbnailPde9 inhibitors with imidazo triazinone backbone
This invention is directed to compounds, which are pde9 enzyme inhibitors. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier.
H. Lundbeck A/s


 Serotonin receptor-targeting compounds and methods patent thumbnailSerotonin receptor-targeting compounds and methods
This invention relates to, in part, compositions and methods that are useful for, inter alia, the treatment of various diseases, including those linked to binding at a serotonin receptor. The compositions include chiral tetrahydronaphthalen-2-amine derivatives.
Northeastern University


 Compositions and methods for the treatment and prevention of antipsychotic medication-induced weight gain patent thumbnailCompositions and methods for the treatment and prevention of antipsychotic medication-induced weight gain
The invention provides methods and compositions for the treatment of a subject having a psychiatric disease or dis order based upon the subject's genotype and/or the number of risk alleles carried by the subject, which risk alleles have been found by the present inventors to predispose a subject to antipsychotic medication induced weight gain (aiwg). The methods of the inven tion also provide for different treatments, or different treatment regimens, for the subject depending on the subject's risk of aiwg.
Centre For Addiction And Mental Health


 Suprametallogels and uses thereof patent thumbnailSuprametallogels and uses thereof
The disclosure provides nanostructures (e.g., nanospheres and nano-paddlewheels) formed through transition metal-ligand (e.g., pd(ii)-, ni(ii)-, or fe(ii)-ligand of formula (a)) coordination and junction self-assembly. The disclosure also provides supramolecular complexes that include the nanostructures connected by divalent linkers y.
Massachusetts Institute Of Technology


Magnetic stimulation methods and devices for therapeutic treatments

Methods and devices producing time varying magnetic field have therapeutic uses. The device contains a coil made of insulated wires, an energy storage device, an energy source and a switch.
Btl Holdings Limited

5-oxa-2-azabicyclo[2.2.2]octan-4-yl and 5-oxa-2-azabicyclo[2.2.1]heptan-4-yl derivatives

The present invention relates to compounds of formula of formula i wherein x, ar, r1, m and n are as described herein, compositions containing compounds of formula i, methods of manufacture of compounds of formula i and methods of treating psychiatric disorders with compounds of formula i.. .
Hoffmann-la Roche Inc.

Composition for use in treating and/or preventing human condition, disorder or diseases

Composition comprising a metal and/or a semimetal, a sodium salt, a tranquilizer, a halogen, a carotenoid, grain, and a neutral gel for example for use in treating and/or preventing a condition, disorder or disease such as pain, metabolic diseases, fatigue, absence of appetite, cramps, immune diseases, inflammatory disease, cancer, neurological and/or psychiatric diseases.. .

Methods and compositions for mitochondrial replacement therapy

The invention features methods, kits, and compositions for mitochondrial replacement in the treatment of disorders arising from mitochondrial dysfunction. The invention also features methods of diagnosing neuropsychiatric (e.g., bipolar disorder) and neurodegenerative disorders based on mitochondrial structural abnormalities..
The Mclean Hospital Corporation

(r)-3-((3s,4s)-3-fluoro-4-(4-hydroxyphenyl)piperidin-1-yl)-1-(4-methylbenzyl)pyrrolidin-2-one and its prodrugs for the treatment of psychiatric disorders

The disclosure generally relates to compounds of formula i, including their salts, as well as compositions and methods of using the compounds. The compounds are ligands for the nr2b nmda receptor and may be useful for the treatment of various disorders of the central nervous system..
Bristol-myers Squibb Company

Process for the preparation of histamine h3 receptor modulators

The present invention is directed to novel processes for the preparation of histamine h3 receptor modulators, in the treatment of for example, cognitive disorders, sleep disorders and/or psychiatric disorders.. .
Janssen Pharmaceutica Nv

Extracranial implantable devices, the treatment of neuropsychiatric disorders

The present disclosure relates to methods, devices, and systems used for the treatment of mood, anxiety, cognitive, and behavioral disorders (collectively, neuropsychiatric disorders) via stimulation of the superficial elements of the trigeminal nerve (“tns”). More specifically, minimally invasive systems, devices and methods of stimulation of the superficial branches of the trigeminal nerve located extracranially in the face, namely the supraorbital, supratrochlear, infraorbital, auriculotemporal, zygomaticotemporal, zygomaticoorbital, zygomaticofacial, nasal and mentalis nerves (also referred to collectively as the superficial trigeminal nerve) are disclosed herein..
Neurosigma, Inc.

Use of 4-aminopyridine to improve neuro-cognitive and/or neuro-psychiatric impairment in patients with demyelinating and other nervous system conditions

Disclosed herein are methods and compositions related to use of aminopyridines, such as 4-aminopyridine, to prove the neuro-cognitive impairments and related neuro-psychiatric impairments of patients with a demyelinating condition such as ms, traumatic brain injury, cerebral palsy, post-radiation encephalopathy.. .
Acorda Therapeutics, Inc.

Method and system to predict response to treatments for mental disorders

The present inventions relates to methods and assays to predict the response of an individual to a psychiatric treatment and to a method to improve medical treatment of a disorder, which is responsive to treatment with a psychiatric treatment.. .
Pathway Genomics Corporation

Methods and pharmaceutical compositions for the treatment of symptoms of anxiety and panic using beta adrenergic receptor antagonist and muscarinic receptor antagonist combinations

The present invention is focused primarily toward pro re nata (“as needed”) treatments for a psychiatric condition or disorder or the symptoms thereof, including the symptoms of acute anxiety and panic in living animals, including humans. The present invention encompasses pharmaceutical compositions as combination therapies containing at least one beta adrenergic receptor antagonist and at least one muscarinic receptor antagonist.
Thomas P. Dooley, Phd.

Pharmaceutical salts of an orexin receptor antagonist

The invention is directed to pharmaceutically acceptable salts of suvorexant, which is an antagonist of orexin receptors. The pharmaceutically acceptable salts of suvorexant are useful in the treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved.
Merck Sharp & Dohme Corp.

Morpholin-pyridine derivatives

The present invention relates to compounds of formula of formula i wherein x, r, l, ar, r1 and n are as described herein, compositions containing compounds of formula i, methods of manufacture of compounds of formula i and methods of treating psychiatric disorders with compounds of formula i.. .
Hoffmann-la Roche Inc.

Cb2 receptor ligands for the treatment of psychiatric disorders

The present invention provides cannabinoid type 2 (cb2) receptor inverse agonists for treating or ameliorating psychiatric disorders. The present invention further provides pharmaceutical compositions comprising 4′-o-methylhonokiol for treating attention deficit hyperactivity disorder (adhd) and tourette's syndrome..
Ariel - University Research And Development Company, Ltd.

Method for cross-diagnostic identification and treatment of neurologic features underpinning mental and emotional disorders

A system and method for diagnosing mental or emotional disorders is disclosed. An affective bci component is incorporated into a closed loop, symptom—responsive psychiatric dbs system.
Massachusetts Institute Of Technology

Technologies for diagnosing neurological or psychiatric illnesses

A technology which enables identifying, via a computer, a vessel in a third image. The third image is obtained from a subtraction of a second image from a first image.
The Trustees Of Columbia University In The City Of New York

System and diagnosis and treatment of neuropsychiatric disorders

An assay for a gch1 allele and associated genotype for the screening, prediction, diagnosis, prognosis, treatment and treatment response of psychiatric, neuropsychiatric, and neurological disorders, such as schizophrenia, schizoaffective disorder and bipolar disorder, and for defining treatments of such disorders. The presence of a variant in the gch1 gene, alone or in conjunction with a measurement of low or altered biopterin, or altered bh4 system measures, is used to screen or diagnose subjects at risk for developing a psychiatric, neuropsychiatric, or neurological disorder.
The Research Foundation For Mental Hygiene, Inc.

Guanidine compounds and use thereof as binding partners for 5-ht5 receptors

Corresponding enantiomeric, diastereomeric and/or tautomeric forms thereof as well as pharmaceutically acceptable salts thereof. The present compound further relates to the use of guanidine compounds as binding partners for 5-ht5 receptors for the treatment of diseases which are modulated by a 5-ht5 receptor activity, in particular for the treatment of neurodegenerative and neuropsychiatric disorders as well as the associated signs, symptoms and dysfunctions..

Methods and compositions for the treatment of post-traumatic stress disorder

Methods and compositions are disclosed to treat neuropsychiatric disorders post-traumatic stress disorder (ptsd). In particular, described herein are angiotensin receptor blockers (arbs), and in particular the combination of one or more arb (such as telmisartan) and an agent that enhances the delivery of the arb across the blood-brain barrier (such as minocycline).

Substituted 5-aminothieno[2,3-c]pyridazine-6-carboxamide analogs as positive allosteric modulators of the muscarinic acetylcholine receptor m4

In one aspect, the invention relates to substituted 5-aminothieno[2,3-c]pyridazine-6-carboxamide analogs, derivatives thereof, and related compounds, which are useful as positive allosteric modulators of the muscarinic acetylcholine receptor m4 (machr m4); synthesis methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of treating neurological and psychiatric disorders associated with muscarinic acetylcholine receptor dysfunction using the compounds and compositions. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention..
Vanderbilt University

Halogenated quinazolin-thf-amines as pde1 inhibitors

The present invention provides halogenated quinazolin-thf-amines as pde1 inhibitors and their use as a medicament, in particular for the treatment of neurodegenerative disorders and psychiatric disorders.. .
H. Lundbeck A/s

Substituted 4-benzyl-3,4-dihydro-2h-benzo[b][1,4]oxazine-2carboxamide analogs as positive allosteric modulators of muscarinic acetycholine receptor m1

In one aspect, the invention relates to n-substituted 3,4-dihydro-benzo[£][1,4]oxazine-2-carboxamide analogs, derivatives thereof, and related compounds, which are useful as positive allosteric modulators of the muscarinic acetylcholine receptor m1 (machr m1); synthesis methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of treating neurological and psychiatric disorders associated with muscarinic acetylcholine receptor dysfunction using the compounds and compositions. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention..
Vanderbilt University

Compositions and methods for treatment of psychiatric disorders

Compositions and methods for the treatment of a unipolar depression containing betaine, and folate. Formulations for oral administration optionally also contain l-methionine..

In vitro diagnosing parkinson's disease

The present invention relates to an in vitro method of diagnosing a neurological disease associated with at least one symptom selected from the group comprising non-motor symptoms, sleep-wake disorders, sensory disorders, neuropsychiatric disorders and cognitive difficulties, comprising measuring the amount of active c-rel factor in a biological sample comprising endogenus c-rel factor from a patient.. .
Fondezione Ospedale Hospital In Venice



Psychiatric topics:
  • Psychiatric
  • Neurological
  • Therapeutical
  • Psychiatric Disorders
  • Enzyme Inhibitor
  • Intestinal Diseases
  • Pathologic
  • Urogenital
  • Pharmaceutically Acceptable Salts
  • Pharmaceutically Acceptable Salt
  • Gastrointestinal Disease
  • Gastrointestinal Diseases
  • Gastrointestinal
  • Recombinant
  • Adverse Effect


  • Follow us on Twitter
    twitter icon@FreshPatents

    ###

    This listing is a sample listing of patent applications related to Psychiatric for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Psychiatric with additional patents listed. Browse our RSS directory or Search for other possible listings.


    0.2446

    file did exist - 2574

    2 - 1 - 51